Skip to main
PODD
PODD logo

Insulet (PODD) Stock Forecast & Price Target

Insulet (PODD) Analyst Ratings

Based on 38 analyst ratings
Buy
Strong Buy 32%
Buy 45%
Hold 16%
Sell 0%
Strong Sell 8%

Bulls say

Insulet demonstrated robust financial performance with global Omnipod sales increasing by 26% year-over-year on an underlying basis in Q4 2024, reaching $586 million. The company attained significant milestones, with over 500,000 active global customers and steady year-over-year utilization and retention rates, indicating a strong momentum in Omnipod adoption across various markets. Additionally, Insulet's 2024 sales totaled $2.07 billion, marking a 22% increase year-over-year, along with an EPS of $3.24 that surpassed consensus estimates, further reinforcing a positive outlook for the company's growth trajectory.

Bears say

The financial analysis of Insulet reveals concerning trends, including a decline in operating margins by 240 basis points year-over-year, raising questions about operational efficiency. Furthermore, the company faces significant challenges with a projected drop of 45-55% in Drug Delivery revenues, alongside weak guidance for overall sales growth, which has fallen slightly short of expectations. These issues, compounded by reliance on third-party distributors and potential competitive pressures, create increased risks to revenue stability and long-term growth prospects.

Insulet (PODD) has been analyzed by 38 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 45% recommend Buy, 16% suggest Holding, 0% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insulet (PODD) Forecast

Analysts have given Insulet (PODD) a Buy based on their latest research and market trends.

According to 38 analysts, Insulet (PODD) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $218.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $218.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insulet (PODD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.